Live Breaking News & Updates on ஆராய்ச்சி பயன்பாடு மட்டும்
Stay updated with breaking news from ஆராய்ச்சி பயன்பாடு மட்டும். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vaccine Ingredient SM-102 Is Safe SciCheck Digest The COVID-19 vaccine from Moderna uses an ingredient called SM-102 to deliver the mRNA that carries instructions for how to develop antibodies against the novel coronavirus. A widely shared video is now spreading the falsehood that SM-102 is harmful, but the warning label it shows is for chloroform, not SM-102. How do we know vaccines are safe?
As with any vaccine, safety is also being monitored as the shots are rolled out to members of the public to ensure there are no side effects of concern. A very small number of severe allergic reactions, for example which are expected with any vaccine haveoccurred with some of the authorized COVID-19 vaccines. The CDC said the reaction – anaphylaxis – occurred in 2 to 5 people per million vaccinated. This reaction “almost always occurs” within a half hour of receiving a shot, and vaccination providers have medicine to immediately tr ....
Product News: DiaSorin releases assay for rapid identification of SARS-CoV-2 variants The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction 21 May 2021 DiaSorin has announced that it has released the Simplexa™ SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction. The assay helps to streamline and speed-up the pre-selection process of positive samples that need further sequencing, maximizing the effectiveness of monitoring programs for the spread of concerning variants. The Simplexa™ SARS-CoV-2 Variants Direct is a Research Use Only assay and is not for use in diagnostics procedures. The assay allows for the in vitro qualitative differential detection of the mutations N501Y, E484K, E484Q, and L452R directly from nasop ....
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020.
· Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix ® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients - FDA Administrative Review complete and Substantive Review in progress - FDA Additional Information Request (AIR) received and response planned for submission in May 2021
- patient enrolment completed after the year end - surgical procedures in progress and sample analysis in preparation - study expected to report headline results in Q4 2021 ....
Published: Apr 19, 2021 Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is being extended beyond the second-year expansion phase by another six months through September 30, 2021. Having successfully achieved all of the milestones of the first and second year phases for the development of an infectious disease digital health and precision medicine platform that connects health ....
2021/04/12 13:30 IRVINE, CA. - News Aktuell - 12 April 2021 - Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval. The Fluxergy Diagnostic System: The Fluxergy Analyzer, which conducts the testing; the Fluxergy Card, a single-use test cartridge and its reagents; and the FluxergyWorks software, to manage the test data. The Fluxergy Test Kit COVID-19 is only available for purchase in the European Union market and any other markets that accept the CE-marking as valid regulatory approval. COURTESY: FLUXERGY, INC. ....